INBRX-106 + pembrolizumab + pemetrexed + carboplatin

**INBRX-106 + pembrolizumab + pemetrexed + carboplatin** is an investigational combination regimen for advanced/metastatic non-squamous non-small cell lung cancer (NSCLC). - **INBRX-106** is a tetravalent OX40 agonist antibody being investigated as an immunotherapy that stimulates the OX40 immune checkpoint to enhance anti-tumor T-cell activity. - **Pembrolizumab** is a PD-1 checkpoint inhibitor monoclonal antibody (marketed as Keytruda) that blocks the interaction between PD-1 and its ligands, restoring immune activity against tumors. - **Pemetrexed** (Alimta) is an antineoplastic agent that inhibits folate-dependent enzymes required for nucleotide synthesis, leading to cytotoxic effects primarily in rapidly dividing cancer cells. - **Carboplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in cancer cells. This regimen combines targeted immunotherapies with cytotoxic chemotherapy, aiming to improve overall survival and progression-free survival in patients with advanced NSCLC lacking EGFR and ALK mutations, particularly those with a good performance status[3][5][1].

Other names

INBRX-106 combinationINBRX106 combinationINBRX 106 combinationpembrolizumab + pemetrexed + carboplatin